ClinicalTrials.gg
Enrolling by invitationNCT06738550Updated Dec 17, 2024

Effect of Agave Inulin on Constipation and Quality of Life in Peritoneal Dialysis Patients.

An interventional study of inulin and Lactulose oral solution in Constipation, Peritoneal Dialysis (PD) and CKD, sponsored by NIN Institute. Enrolling by invitation at 1 site in Mexico. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2024-12-17.

Sponsored by NIN Institute · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Registered 1 year 6 months after the study started (first participant enrolled Mar 2023, registered Sep 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
45
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

This is a randomized controlled clinical study realized in the nephrology service of the Centro Medico ISSEMyM hospital in Metepec, State of Mexico, including new patients on Peritoneal Dialysis (PD) over 18 years of age with constipation criteria, the Bristol scale and Rome IV Criteria were used, with a 6-month follow-up with a personalized diet plan, intervention group supplementation with agave Tequiliana blue variety inulin with an initial dose of 9 grams per day, the control gruop recived lactulosa. Data were obtained from the clinical history comorbidities present in the patients, anthropometric data such as weight, % of fat, % of body water, Fat Free Mass (FFM) obtained using a TANITA scale model BC-533; skin folds were obtained using a slim Guide plicometer, dietary data such as energy intake (kcal), protein intake, fluid intake, were estimated using a 24 hr reminder. A questionnaire was also applied to measure gastrointestinal symptoms and their evolution with the intervention, in addition to the KDQOL-SF to evaluate the quality of life of the patients.

Read the detailed description

Constipation affects a large part of the population with Chronic Kidney Disease (CKD), and in Peritoneal Dialysis (PD) it is the most common symptom derived from multiple factors, including dietary restrictions causing insufficient fiber intake, water restriction, drug consumption and the change in the intestinal microbiota derived from uremic toxins during this stage, leading to a poor quality of life in the patient and consequently an alteration in the patient\'s nutritional status. In turn, constipation has become a risk factor in the development of cardiovascular diseases, of which patients with CKD have a higher incidence. This research aims to determine the effects of agave inulin supplementation on constipation and quality of life in peritoneal dialysis patients in order to establish a strategy to support patient treatment and improve uremic syndrome.

Lactulose syrup is usually used to prevent and treat constipation in doses from 10 ml every 8 hours.

The present research aims to determine the effects that agave inulin supplementation may have on constipation and quality of life in peritoneal dialysis patients, and to establish a strategy to support the patient\'s treatment and improve uremic syndrome.

Stage 1 Patients will be selected by the peritoneal dialysis team to identify the patients who start RRT, once identified, they will be referred to the nutrition office, where an initial evaluation of the patient will be made and if they meet the inclusion criteria, the informed consent will be explained and if they accept, they will be randomly assigned to the group they are assigned to. The laboratories requested to the patients are the same as those routinely requested by the treating physician. The characteristics of the nutritional intervention are detailed below. The characteristics of the first visit are detailed below.

Visit 1:

  1. Evaluation of selection/inclusion criteria
  2. Assessment in medical consultation
  3. Signing of consent form.
  4. Initial evaluation (File with: clinical, anthropometric, biochemical, dietary data).
  5. Constipation evaluation with Bristol scale
  6. Evaluation of quality of life with KDQOL-SF questionnaire.
  7. Delivery of food plan and nutritional recommendations
  8. Indication and delivery of the supplement according to the group.
  9. Indicate that unfinished product should be returned.
  10. Request for laboratory tests (routine tests that the nephrologist requests consultation after consultation).
  11. Appointment every 30 days for delivery of supplement and adherence evaluation.

Stage 2 In the second stage, patients are followed month by month for medical and nutritional evaluation, evaluating anthropometry, biochemistry, clinical signs, patient\'s diet, therapeutic adherence to supplementation, evaluation of gastrointestinal symptoms and constipation, and evaluation of quality of life. The corresponding data are recorded in a database. The characteristics of the visit are detailed below.

Visit 2, 3, 4 and 5:

  1. Intermediate medical evaluation
  2. Intermediate evaluation (File with: clinical, anthropometric, biochemical, dietary data, adherence evaluation).
  3. Constipation evaluation with Bristol scale and roma criteria.
  4. Supplement delivery
  5. Request for laboratory tests (routine tests requested by the nephrologist consultation after consultation).
  6. Appointment every 30 days.

Stage 3 In this stage the supplementation is suspended, a medical and nutritional evaluation is made evaluating anthropometry, biochemistry, clinical signs, patient\'s diet, therapeutic adherence to supplementation, evaluation of gastrointestinal symptoms and constipation and evaluation of quality of life. The corresponding data are recorded in a database. The characteristics of the visit are detailed below.

Visit 6: discontinue supplementation.

  1. Final evaluation (clinical record with anthropometric, clinical, biochemical and dietary data, evaluation of therapeutic adherence).
  2. Evaluation of constipation with Bristol scale and roma criteria.
  3. Request for laboratory tests (routine tests that the nephrologist requests consultation after consultation).
  4. Appointment after 30 days. In this last stage, the patient will be seen again after one month to evaluate the post-supplementation period.

In this last stage, the patient will be seen again after one month to evaluate the post-supplementation period.

Visit 7:

  1. Post-intervention period evaluation (file with: clinical, anthropometric, biochemical, dietary data).
  2. Evaluation of constipation with Bristol scale and roma criteria.
  3. Evaluation of quality of life with KDQOL-SF questionnaire.

Characteristics of the nutritional intervention:

In the nutritional intervention, the patient\'s family medical history, clinical indicators such as T/A, signs of nutritional deficiency such as dehydration, muscle and fat depletion, edema and gastrointestinal symptoms and degree of constipation will be evaluated by clinical history.

Biochemical indicators are tests that are commonly requested in nephrology follow-up consultations, will be evaluated.

For the evaluation of anthropometric indicators, body composition will be evaluated by means of anthropometry (plyometry and circumferences) and a Tanita scale, identifying the patient\'s fat and muscle compartment; in the dietary evaluation, the intake of energy, carbohydrates, lipids and proteins will be evaluated by means of a 24-hour reminder. With the above, a nutritional diagnosis is made and a dietary plan for the patient that includes: general recommendations, explanation of portions, explanation of the food for renal disease and a menu with food options that the patient can follow and exchange with the list of foods provided.

Ethical considerations. Requesting their signature for consent. Human research guidelines will be respected according to \"good clinical practice\". The protocol will be submitted to the Bioethics Committee of the Centro Medico ISSEMyM, Metepec, Edo. México. Care will be taken to respect the recommendations of the Helsinki Declaration in its last correction made during the 64th Annual Assembly organized by the World Medical Association (2013).

02

Conditions studied

  • Constipation
  • Peritoneal Dialysis (PD)
  • CKD
  • Quality of Life (QOL)

Browse trials for

Keywords

  • CKD
  • Peritoneal Dialysis (PD)
  • Constipation
  • Quality of life (QOL)
  • Gastrointestinal symtoms
03

In context

Constipation

1,051 studies on the registry are indexed under Constipation; 163 are open to participants now.

This study's planned enrollment of 45 is below the median of 75 across 889 interventional studies indexed under Constipation.

Browse Constipation studies →

Lead sponsor

NIN Institute is the lead sponsor of 3 studies on the registry; 2 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Over 18 years
  • Beginning of peritoneal dialysis in the last month
  • Constipation
  • Medical follow-up by nephrology every month
  • Without Irritable Bowel Syndrome
  • No frailty criteria

Exclusion criteria

Exclusion Criteria:

  • Patients who don\'t to take the supplement
  • Patients with diarrhea
  • Patients with a diagnosed intestinal disorder
  • Allergic to any ingredient of the supplement.
  • Previous probiotic and/or prebiotic supplementation in the last month
  • Diagnosis of comorbidities such as cancer, decompensated heart failure, decompensated pulmonary disease, decompensated liver disease, , infection present within the last 3 months (chronic and/or acute), stroke and malabsorption syndrome.
  • Hospitalizations within the last month for peritonitis
  • Pregnant women
  • Patients with psychiatric illnesses
Terms in these criteria, in plain language(1)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

HIV

The human immunodeficiency virus, which weakens the immune system.

Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
45 participants (estimated)

Study arms

  • Experimental
    Inulina

    In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided

    Dietary Supplement: inulin

  • Placebo comparator
    Lactulosa

    In the patients of the control group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours

    Drug: Lactulose oral solution

Interventions

  • Dietary supplementinulin

    In the patients of the experimental group, the nutritional intervention is personalized, agave inulin supplementation is provided 9 gr per day, A 6-month follow-up is provided

    Also known as: Inulin prebiotic

  • DrugLactulose oral solution

    In the patients of the experimental group, the nutritional intervention is personalized, A 6-month follow-up is provided and taken syrup lactulose 10 ml every 8 hours

06

What researchers measure

Primary outcomes

  1. Constipation

    Change stool consistency as assessed by the Bristol scale 1 and 2 is Cosntipacion 3 and 4 is Normal 5, 6 and 7 is diarrhea

    Time frame: Baseline intervetion and 6 months

  2. Gastrointestinal symptoms

    Changing the intensity of gastrointestinal symptoms caused by CKD and constipation as assessed with the PAC-SYM QUESTIONNAIRE Designed to assess the patient's experience of constipation over two weeks by measuring symptoms and symptom severity. It is a self-reported questionnaire consisting of 12 symptoms divided into three domains: abdominal, rectal and stool, with responses rated on a 5-point Likert scale. Scoring The PAC-SYM is a tool that can be used to understand the severity of your patient's constipation and help you identify key symptom areas. A total PAC-SYM score ranges from 0 to 48 with a low score indicating fewer symptoms and of lower severity. Absence of symptom = 0 Mild = 1 Moderate = 2 Severe = 3 Very severe = 4

    Time frame: Baseline intervention and 6 months

Secondary outcomes

  1. Dietary intake (kcal/kg/day)

    Changes in dietary caloric intake of patients at baseline and month 6

    Time frame: baseline intervention and 6 months

07

Study locations

1 site
  • Centro Medico ISSEMyM, Toluca
    Metepec, Estado de Mexico 52170, Mexico
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2023 to primary completion in Jul 2024, 16 months.

Of 71 industry-sponsored interventional studies with no phase under Constipation, half reached primary completion within 11 months of starting (the median), counting those still running; a quarter within 5 and three quarters within 16. This study's 16 months is above that.

Counting every sponsor, half of 317 studies reached it within 14 months; a quarter within 6 and three quarters within 28.

How these figures are worked out, and which studies are left out of them.

Registered
Sep 23, 2024
First posted
Dec 17, 2024
StartActual
Mar 1, 2023
Primary completionActual
Jul 30, 2024
CompletionEst.
Aug 31, 2025
Last update
Dec 17, 2024
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 17, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT06738550
Lead sponsor
NIN Institute
Responsible party
Ari Cisneros-Hernández (Principal Investigator, Centro Medico Issemym) — Principal investigator
First posted
Dec 17, 2024
Start date
Mar 1, 2023
Primary completion
Jul 30, 2024
Completion
Aug 31, 2025 (estimated)
Last update
Dec 17, 2024

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Inulin

Start the discussion